Caxton Associates (New York)’s Lexicon Pharmaceuticals LXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-46,281
| Closed | -$88.4K | – | 570 |
|
|
2022
Q4 | $88.4K | Sell |
46,281
-8,500
| -16% | -$16.2K | 0.01% | 404 |
|
|
2022
Q3 | $131K | Buy |
+54,781
| New | +$131K | 0.02% | 418 |
|
|
2021
Q2 | – | Sell |
-28,705
| Closed | -$168K | – | 521 |
|
|
2021
Q1 | $168K | Buy |
28,705
+17,958
| +167% | +$105K | 0.02% | 358 |
|
|
2020
Q4 | $37K | Buy |
+10,747
| New | +$37K | ﹤0.01% | 115 |
|